Stawicki, Sabina

[["dc.bibliographiccitation.firstpage","26"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Molecular Psychiatry"],["dc.bibliographiccitation.lastpage","36"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Wüstenberg, Torsten"],["dc.contributor.author","Begemann, Martin"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Gefeller, Olaf"],["dc.contributor.author","Stawicki, S."],["dc.contributor.author","Hinze-Selch, D."],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Aldenhoff, Josef B."],["dc.contributor.author","Knauth, Michael"],["dc.contributor.author","Nave, Klaus-Armin"],["dc.contributor.author","Ehrenreich, Hanhelore"],["dc.date.accessioned","2017-09-07T11:46:27Z"],["dc.date.available","2017-09-07T11:46:27Z"],["dc.date.issued","2011"],["dc.description.abstract","Neurodevelopmental abnormalities together with neurodegenerative processes contribute to schizophrenia, an etiologically heterogeneous, complex disease phenotype that has been difficult to model in animals. The neurodegenerative component of schizophrenia is best documented by magnetic resonance imaging (MRI), demonstrating progressive cortical gray matter loss over time. No treatment exists to counteract this slowly proceeding atrophy. The hematopoietic growth factor erythropoietin (EPO) is neuroprotective in animals. Here, we show by voxel-based morphometry in 32 human subjects in a placebo-controlled study that weekly high-dose EPO for as little as 3 months halts the progressive atrophy in brain areas typically affected in schizophrenia, including hippocampus, amygdala, nucleus accumbens, and several neocortical areas. Specifically, gray matter protection is highly associated with improvement in attention and memory functions. These findings suggest that a neuroprotective strategy is effective against common pathophysiological features of schizophrenic patients, and strongly encourage follow-up studies to optimize EPO treatment dose and duration."],["dc.identifier.doi","10.1038/mp.2010.51"],["dc.identifier.gro","3150516"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6267"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7289"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject","hematopoietic growth factor; neuroregeneration; neuroprotection; voxel-based morphometry; brain atrophy; cognition; schizophrenia"],["dc.title","Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","206"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Molecular Psychiatry"],["dc.bibliographiccitation.lastpage","220"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Hinze-Selch, D."],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Knolle-Veentjer, S."],["dc.contributor.author","Wilms, S."],["dc.contributor.author","Heinz, G."],["dc.contributor.author","Erdag, S."],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Ritzen, M."],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Wagner, M."],["dc.contributor.author","Schneider, U."],["dc.contributor.author","Bohn, Matthias"],["dc.contributor.author","Huber, Martin"],["dc.contributor.author","Czernik, Adelheid"],["dc.contributor.author","Pollmacher, T."],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Sirén, A-L."],["dc.contributor.author","Klosterkötter, J."],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Aldenhoff, Josef B."],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2007"],["dc.description.abstract","Schizophrenia is increasingly recognized as a neurodevelopmental disease with an additional degenerative component, comprising cognitive decline and loss of cortical gray matter. We hypothesized that a neuroprotective/neurotrophic add-on strategy, recombinant human erythropoietin (rhEPO) in addition to stable antipsychotic medication, may be able to improve cognitive function even in chronic schizophrenic patients. Therefore, we designed a double-blind, placebo-controlled, randomized, multicenter, proof-of-principle (phase II) study. This study had a total duration of 2 years and an individual duration of 12 weeks with an additional safety visit at 16 weeks. Chronic schizophrenic men (N=39) with defined cognitive deficit (greater than or equal to1 s.d. below normal in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)), stable medication and disease state, were treated for 3 months with a weekly short (15 min) intravenous infusion of 40 000 IU rhEPO (N=20) or placebo (N=19). Main outcome measure was schizophrenia-relevant cognitive function at week 12. The neuropsychological test set (RBANS subtests delayed memory, language–semantic fluency, attention and Wisconsin Card Sorting Test (WCST-64) – perseverative errors) was applied over 2 days at baseline, 2 weeks, 4 weeks and 12 weeks of study participation. Both placebo and rhEPO patients improved in all evaluated categories. Patients receiving rhEPO showed a significant improvement over placebo patients in schizophrenia-related cognitive performance (RBANS subtests, WCST-64), but no effects on psychopathology or social functioning. Also, a significant decline in serum levels of S100B, a glial damage marker, occurred upon rhEPO. The fact that rhEPO is the first compound to exert a selective and lasting beneficial effect on cognition should encourage new treatment strategies for schizophrenia."],["dc.identifier.doi","10.1038/sj.mp.4001907"],["dc.identifier.gro","3150509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7281"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","1359-4184"],["dc.subject","S100B; plasticity; neuropsychology; psychopathology; high-dose EPO"],["dc.title","Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]